Alpha Tau Medical Ltd. (DRTS) stock
Close on Nov 12, 2026Market cap $1.18BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.18B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 26.69
- Dividend yield
- –
- Free cash flow yield
- -2.79%
Fundamentals
- Net income
- -$42.63M
- EPS, diluted
- -$0.53
- Free cash flow
- -$32.76M
Trading
- Previous close
- $14.02
- Open
- $13.92
- Day's range
- $13.15 – $13.93
- Volume
- 612,803
- Average volume (20 days)
- 535,890
- Beta (5 years)
- 1.05
- 52-week range
- $3.43 – $15.79
- RSI (14 days)
- 47.3
- Volatility (1 year)
- 77.3%
- Relative volume
- 1.11×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DRTS | S&P 500 | Difference | DRTS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.3% | -2.7% | −3.6 pts | ||
| 3 months | -3.7% | -1.7% | −1.9 pts | ||
| Year to date | +169.9% | +11.9% | +158.0 pts | ||
| 1 year | +236.5% | +12.0% | +224.5 pts | ||
| 3 years | +331.0% | +78.2% | +252.8 pts | +62.7% | +21.2% |
| 5 years | +34.5% | +73.2% | −38.7 pts | +6.1% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alpha Tau Medical filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Alpha Tau Medical
Surgical & Medical Instruments & Apparatus
Alpha Tau Medical Ltd. is a clinical-stage medical device oncology therapeutics company focused on the development of its proprietary Alpha DaRT technology. The technology is designed to treat solid tumors through alpha irradiation via the intratumoral insertion of radium-224 impregnated sources, providing localized radiotherapy. The company evaluates its treatment across multiple cancer types, including skin, oral, pancreatic, prostate, lung, liver, and brain cancers. Alpha Tau Medical does not currently market products commercially or generate revenue, and its activities center on clinical, scientific, and preclinical programs for cancer patients.
Company profile, executives and historyAlpha Tau Medical stock: common questions
What is Alpha Tau Medical's stock price?
DRTS closed at $13.36 on Nov 12, 2026, down 4.71% on the day. Over the past 52 weeks it traded between $3.43 and $15.79.
What is Alpha Tau Medical's market cap?
Alpha Tau Medical was worth $1.18B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is DRTS's P/E ratio?
Alpha Tau Medical lost money over fiscal 2025 (diluted EPS -$0.53), so it has no meaningful P/E ratio.
Does Alpha Tau Medical pay a dividend?
No. Alpha Tau Medical has not paid a cash dividend over the last twelve months.
How has DRTS stock performed over the past year?
Including dividends, DRTS returned +236.5% over the past year, against +12.0% for the S&P 500.
Who are Alpha Tau Medical's competitors?
Companies most similar to Alpha Tau Medical by business, industry and size include CNSY, RDGL, NVCR, ICCM, DCTH.
See a number that looks wrong?